Literature DB >> 2157200

Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication.

J P Leonetti1, P Machy, G Degols, B Lebleu, L Leserman.   

Abstract

Mouse L929 cells were incubated with antibody-targeted liposomes containing oligodeoxyribonucleotides (oligomers). When the oligomer was a 15-mer complementary to the 5'-end region of the mRNA encoding the N protein of vesicular stomatitis virus, the cells became less permissive for multiplication of that virus; greater than 95% reduction of viral multiplication was achieved. Protection was not seen for "empty" liposomes, liposomes containing a random oligomer sequence, or liposomes containing a sequence complementary to the 5' end of c-myc protooncogene mRNA targeted by the same antibody, nor was it seen when the liposomes containing the N-protein antisense oligomer were targeted by an antibody that does not bind to L929 cells. Antibody-bearing liposomes containing antisense oligomers thus have a double specificity: a particular cell selected by the targeting antibody on the liposome and a particular mRNA in the cell selected by sequence complementarity with the liposome-encapsulated oligomer. Nonencapsulated oligomers are sensitive to nucleases and usually must be administered to cells at high concentrations. Oligomers encapsulated in liposomes resist DNase and are active in amounts 1-2 orders of magnitude lower than for those reported for unencapsulated oligomer sequences.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157200      PMCID: PMC53706          DOI: 10.1073/pnas.87.7.2448

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Major histocompatibility complex class I molecules internalized via coated pits in T lymphocytes.

Authors:  P Machy; A Truneh; D Gennaro; S Hoffstein
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

2.  Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.

Authors:  M Lemaitre; B Bayard; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

3.  Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylphosphonates.

Authors:  C H Agris; K R Blake; P S Miller; M P Reddy; P O Ts'o
Journal:  Biochemistry       Date:  1986-10-07       Impact factor: 3.162

4.  Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.

Authors:  C C Smith; L Aurelian; M P Reddy; P S Miller; P O Ts'o
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

5.  Endocytosis of liposomes bound to cell surface proteins measured by flow cytofluorometry.

Authors:  A Truneh; Z Mishal; J Barbet; P Machy; L D Leserman
Journal:  Biochem J       Date:  1983-07-15       Impact factor: 3.857

6.  A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1.

Authors:  R Heikkila; G Schwab; E Wickstrom; S L Loke; D H Pluznik; R Watt; L M Neckers
Journal:  Nature       Date:  1987 Jul 30-Aug 5       Impact factor: 49.962

7.  Endocytosis and de novo expression of major histocompatibility complex encoded class I molecules: kinetic and ultrastructural studies.

Authors:  P Machy; A Truneh; D Gennaro; S Hoffstein
Journal:  Eur J Cell Biol       Date:  1987-12       Impact factor: 4.492

8.  Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides.

Authors:  J P Leonetti; B Rayner; M Lemaitre; C Gagnor; P G Milhaud; J L Imbach; B Lebleu
Journal:  Gene       Date:  1988-12-10       Impact factor: 3.688

9.  Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene.

Authors:  J A Zaia; J J Rossi; G J Murakawa; P A Spallone; D A Stephens; B E Kaplan; R Eritja; R B Wallace; E M Cantin
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

10.  Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours.

Authors:  O Bernard; S Cory; S Gerondakis; E Webb; J M Adams
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  27 in total

1.  The vacuum UV CD spectra of G.G.C triplexes.

Authors:  K H Johnson; R H Durland; M E Hogan
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

2.  Acoustic characterization of echogenic liposomes: frequency-dependent attenuation and backscatter.

Authors:  Jonathan A Kopechek; Kevin J Haworth; Jason L Raymond; T Douglas Mast; Stephen R Perrin; Melvin E Klegerman; Shaoling Huang; Tyrone M Porter; David D McPherson; Christy K Holland
Journal:  J Acoust Soc Am       Date:  2011-11       Impact factor: 1.840

3.  Thermodynamics and dynamics of the formation of spherical lipid vesicles.

Authors:  Ernesto Hernández-Zapata; Luciano Martínez-Balbuena; Iván Santamaría-Holek
Journal:  J Biol Phys       Date:  2009-06-25       Impact factor: 1.365

Review 4.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

5.  ECHOGENIC LIPSOMES FOR TARGETED DRUG DELIVERY.

Authors:  Christy K Holland; David D McPherson
Journal:  Proc IEEE Int Symp Biomed Imaging       Date:  2009-06-28

Review 6.  Ribozymes: biology, biochemistry, and implications for clinical medicine.

Authors:  M Kiehntopf; E L Esquivel; M A Brach; F Herrmann
Journal:  J Mol Med (Berl)       Date:  1995-02       Impact factor: 4.599

7.  Synthesis and hybridization properties of oligonucleotides containing 2'-O-modified ribonucleotides.

Authors:  T H Keller; R Häner
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

Review 8.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

9.  Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action.

Authors:  C Ropert; C Malvy; P Couvreur
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

Review 10.  Reactive oligonucleotide derivatives as gene-targeted biologically active compounds and affinity probes.

Authors:  D G Knorre; V V Vlassov
Journal:  Genetica       Date:  1991       Impact factor: 1.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.